Cardio 10 Deck 6 Flashcards

1
Q

Pathophysiology of Heart Failure

A

Complex syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricles to fill or eject blood (cardiac output [CO])

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Determinants of ventricular function

A

Preload, afterload
Contractility, stroke volume, CO
Heart rate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Left ventricular dysfunction

A

Increase in end systolic volume
Increase in end diastolic volume
Pulmonary congestion
Decreased CO, hypoperfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Compensatory systems

A

Sympathetic activation

Renin–angiotensin–aldosterone system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

American College of Cardiology Heart Failure grages

A

A through D

D is the most severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

New York heart failure grades

A

Progresses from 1 to 4

4 is the most severe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Stage A treatment

A

Lifestyle modification: dyslipidemia, diabetes, hypertension (diuretics or angiotensin-converting enzyme inhibitors [ACEIs])

ACEIs are drug of choice in patients with diabetes.

Angiotensin II receptor blockers (ARBs) are considered in ACEI-intolerant patients, but more expensive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

ACE drug of choice in

A

patients with diabetes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Angiotensin II receptor blockers (ARBs) are considered

A

in ACEI-intolerant patients, but more expensive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Stage B treatement

A

ACEIs in all patients, ARBs for those who cannot tolerate an ACEI
Beta blockers in most

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Stage C treatment

A

ACEIs and beta blockers in all patients
Diuretics, digoxin
Spironolactone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Stage D treatment

A

Entresto
Inotropes: dobutamine
Ventricular assist device, transplantation, hospice care

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Coronary artery disease

medications used

A

Nitrites

Aspirin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Chronic atrial fibrillation

medications used

A

Warfarin or other new anticoagulants that reduce risk of stroke

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Diabetes medications used

A

ACEIs
Thiazides: may increase glucose levels
Beta blockers avoided

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Hypertension

Medication used

A

Use of diuretics early to decrease preload

ACEIs

17
Q

Hyperlipidemia medication used

A

statins

18
Q

Infants and children

medication used

A

Digoxin, thiazide, and loop diuretics all used

19
Q

Pregnancy Medications used

A

ACEIs contraindicated in pregnancy

Diuretics may decrease placental perfusion

20
Q

Treatment Considerations for heart failure

A

Early therapy works best.
As heart failure progresses, non-selective beta blocker with both alpha and beta impact work better than cardioselective types.
The advent of neprilysyn inhibitors (i.e. Entresto) has dramatically decreased risk of death and hospitalizations.

21
Q

Monitoring Heart Failure

A
Functional capacity
Fluid status
Weight changes
Jugular venous distension 
Cardiac rhythm
Laboratory tests
Electrolytes
Creatinine 
Thyroid and liver function
22
Q

Patient Education for heart failure

A

Treatment plan
Pathophysiology and chronicity of heart failure
Home monitoring
Drug therapy
Patients should take exactly as directed.
Patients should not miss or double doses.

23
Q

Digoxin MOA

A

inhibits sodium/potassium ATPS pump in myocardial cells. Promotes influx of calcium. Increases contractility.

24
Q

Digoxin Pharmacokiniteics

A

Readily abosrobed from teh GI tract. Widly distributed protein binding. Half life is 36-48 hours

PO 0.5 - 2 hours peak 2-8 hours durtation 3-4 days

25
Q

Digoxin drug interactions

A

amiodarone may increase toxicity

beta blockers, calcium chalen blockers

potassium depleting diuretics my increase toxicity due to hyopcoemia

26
Q

digoxin loading dose

A

not recomended for heart failure

27
Q

digoxin therapeutic serum level

A

0.8 - 2 ml

28
Q

digoxin toxic serum level

A

greater than 2mg

29
Q

digoxin monitoring

A

apical pulse rate

<60 hold drug

30
Q

Antidoe for digoxin

A

Digoxin immune FAB

31
Q

Digoxin toxicity S/S

A

GI distrbances, neurologic abnomralites, fatigue, weakness, headake, depression, facial pain, personality changes, halows, bradicardia

32
Q

Enteresto class

A

combination of sacubitril, a neprilysin inhibitor and valsrtan, an angiotensin II receptor blocker

33
Q

Entresto MOA

A

Sacubitril inhibits neprilysin increasing peptide levels that are degraded by neprilysin. Valsartan directly antagonizes angiotensin II receptors, blocks vasocnstrictor aldosering secreing effects of angiotensin II

Decreases risk of mortality in pts with HF. prodcues vasodilation, decreases periphearl resistance, decreases b/p

34
Q

Enteresto avoid in

A

pregnancy may cause fetal harm. Unknoinw if distributed in breast milk

35
Q

Enteresto interactions

A

ACE inhibitors, may cause angioedema, potassium sapring diuretics, may increase risk of hyperkalemia. NSAID may wrosen reanl function.

Ginger, ginseng, licorice may worsen hypertension

36
Q

HF Dose Enteresto

A

initially 49 to 51 mg twice daily. May double dose after 2 to 4 weeks

37
Q

Enteresto ADR

A

cough, dizinees

angioeima, hypotension, imparied renal function, elevated serum creatinine. renal imparient.

38
Q

Enteresto evaluation

A

monitor BMP. Serum BUN, Potassium. Montor for hyperkalema and hypotension.

39
Q

Enteresto if hypotension occurs

A

place patietn in trandelmeberg position. alter dose or inerupt treatment. Screan for dug interactions.